Literature DB >> 8627264

Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1.

K Schønning1, B Jansson, S Olofsson, J E Hansen.   

Abstract

The V3 loop of the human immunodeficiency virus (HIV) surface protein, gp 120, constitutes a principal neutralizing determinant. HIV strains lacking a naturally conserved N-linked oligosaccharide (at position 306) within the V3 loop are highly sensitive to neutralization. We subjected molecular clones of HIV(LAI) lacking this 306N-glycan to in vitro immune selection with MAbs directed against the V3 loop. In all, ten clones were characterized, and all proved resistant to V3-directed neutralization. Sequencing of the V3 loop revealed that six of the clones had become resistant at least partly by reacquisition of the 306N-glycan. Only two of the clones possessed mutations within the binding site of the antibody itself, while the two remaining clones did not display changes within the V3 loop itself. Thus, HIV strains lacking the 306N-glycan primarily develop resistance to V3-directed neutralization through acquisition of the specific oligosaccharide. This demonstrates that protein glycosylation can be a primary modifier of virus antigenicity of possible importance for the interaction of HIV with the host immune response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627264     DOI: 10.1099/0022-1317-77-4-753

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  17 in total

1.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

2.  The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Authors:  Miroslaw K Gorny; Kathy Revesz; Constance Williams; Barbara Volsky; Mark K Louder; Christopher A Anyangwe; Chavdar Krachmarov; Samuel C Kayman; Abraham Pinter; Arthur Nadas; Phillipe N Nyambi; John R Mascola; Susan Zolla-Pazner
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities.

Authors:  Chavdar Krachmarov; Zhong Lai; William J Honnen; Aidy Salomon; Miroslaw K Gorny; Susan Zolla-Pazner; James Robinson; Abraham Pinter
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

4.  Conserved, N-linked carbohydrates of human immunodeficiency virus type 1 gp41 are largely dispensable for viral replication.

Authors:  W E Johnson; J M Sauvron; R C Desrosiers
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.

Authors:  M T Esser; T Mori; I Mondor; Q J Sattentau; B Dey; E A Berger; M R Boyd; J D Lifson
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism.

Authors:  R A Ogert; M K Lee; W Ross; A Buckler-White; M A Martin; M W Cho
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.

Authors:  D C Montefiori; J T Safrit; S L Lydy; A P Barry; M Bilska; H T Vo; M Klein; J Tartaglia; H L Robinson; B Rovinski
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

8.  Characterization of primary isolate-like variants of simian-human immunodeficiency virus.

Authors:  J M Crawford; P L Earl; B Moss; K A Reimann; M S Wyand; K H Manson; M Bilska; J T Zhou; C D Pauza; P W Parren; D R Burton; J G Sodroski; N L Letvin; D C Montefiori
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

9.  Location-specific, unequal contribution of the N glycans in simian immunodeficiency virus gp120 to viral infectivity and removal of multiple glycans without disturbing infectivity.

Authors:  S Ohgimoto; T Shioda; K Mori; E E Nakayama; H Hu; Y Nagai
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

10.  Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.

Authors:  Kelly Stefano Cole; Jonathan D Steckbeck; Jennifer L Rowles; Ronald C Desrosiers; Ronald C Montelaro
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.